

[PICTURES IN CLINICAL MEDICINE]


Cerebrotendinous Xanthomatosis with Nodular-hypertrophy of the Lumbosacral Roots

Tomoyo Hashimoto, Yusuke Sennari, Kazumasa Okada and Hiroaki Adachi

Key words: cerebrotendinous xanthomatosis, sterol 27-hydroxylase (*CYP27*) gene, root hypertrophy, magnetic resonance neurography

(Intern Med 57: 1669-1670, 2018)

(DOI: 10.2169/internalmedicine.9883-17)



Picture.

A 39-year-old man with cerebrotendinous xanthomatosis (CTX) had a history of mental retardation (from age 4), cerebellar ataxia and spastic paraparesis (age 33), and cataracts (age 39). The cholestanol level was elevated in the serum (49.6 $\mu\text{g/mL}$, normal 2.35 ± 0.73 $\mu\text{g/mL}$). A genetic analysis revealed c.1421G>A homozygous type in the sterol 27-hydroxylase (*CYP27*) gene (1). Brain magnetic resonance imaging (MRI) showed cerebral and cerebellar atrophy with signal abnormality around the dentate nucleus and pyramidal tract (arrows Picture A and B; T1-weighted fluid-attenuated recovery sequences). The lesions demonstrated a high signal on T1- and T2-weighted images. Multiple nodular thicken-

ing of the nerve roots and trunks of the lumbosacral plexus was detected without gadolinium enhancement on MRI and MR neurography (MRN) (arrowheads Picture C; T2-weighted MRI, Picture D; diffusion-weighted MRN obtained with post-processing with maximum intensity projection). Given that the peripheral nerves are involved in CTX (2), the CTX diagnosis may be enhanced by the detection of spinal root hypertrophy on MRI.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

The authors thank Dr. Shingo Koyama of the Department of Neurology, Hematology, Metabolism, Endocrinology, and Diabetology, Yamagata University Faculty of Medicine, Yamagata, Japan, for his help in the gene analysis. We also thank Dr. Norihiro Ohnari, Dr. Shingo Kakeda, and Prof. Yukunori Korogi of the Department of Radiology, University of Occupational and Environmental Health School of Medicine, for their technical assistance.

References

1. Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and mo-

lecular genetic characteristics of patients with cerebrotendinous xanthomatosis. *Brain* **123**: 908-919, 2000.

2. Ginanneschi F, Mignarri A, Mondelli M, et al. Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. *J Neurol* **260**: 268-274, 2013.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

© 2018 The Japanese Society of Internal Medicine
Intern Med 57: 1669-1670, 2018